Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming
Open accessPublished version of a preprint
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, tic-like head-body twitches and anxiety. These behaviors closely resemble pathological self-grooming behaviors observed in humans in conditions that overlap with OCD. Following a preliminary report that the tryptaminergic psychedelic, psilocybin, may reduce symptoms in patients with OCD, we undertook a randomized controlled trial of psilocybin in 50 SAPAP3 KO mice (28 male, 22 female). Mice that fulfilled inclusion criteria were randomly assigned to a single intraperitoneal injection of psilocybin (4.4 mg/kg), psychedelic mushroom extract (encompassing the same psilocybin dose) or vehicle control and were evaluated after 2, 12, and 21 days by a rater blind to treatment allocation for grooming characteristics, head-body twitches, anxiety, and other behavioral features. Mice treated with vehicle (n = 18) manifested a 118.71 ± 95.96% increase in total self-grooming (the primary outcome measure) over the 21-day observation period. In contrast, total self-grooming decreased by 14.60 ± 17.90% in mice treated with psilocybin (n = 16) and by 19.20 ± 20.05% in mice treated with psychedelic mushroom extract (n = 16) (p = 0.001 for effect of time; p = 0.0001 for time × treatment interaction). Five mice were dropped from the vehicle group because they developed skin lesions; 4 from the psilocybin group and none from the psychedelic mushroom extract group. Secondary outcome measures such as head-body twitches and anxiety all showed a significant improvement over 21 days. Notably, in mice that responded to psilocybin (n = 12) and psychedelic mushroom extract (n = 13), the beneficial effect of a single treatment persisted up to 7 weeks. Mice initially treated with vehicle and non-responsive, showed a clear and lasting therapeutic response when treated with a single dose of psilocybin or psychedelic mushroom extract and followed for a further 3 weeks. While equivalent to psilocybin in overall effect on self-grooming, psychedelic mushroom extract showed superior effects in alleviating head-body twitches and anxiety. These findings strongly justify clinical trials of psilocybin in the treatment of OCD and further studies aimed at elucidating mechanisms that underlie the long-term effects to alleviate excessive self-grooming observed in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148 · cited 1×
“A Cohen ’ s Kappa score between 0.61 and 0.8 is considered substantial agreement and score between 0.8 and 1 is considered almost perfect agreement [31].”
InfluentialThe epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771 · cited 1×
“Obsessive-compulsive disorder (OCD) affects 2 – 3% of the US population and is characterized by intrusive thoughts (obsessions) and repetitive actions (compulsions) [1, 2].”
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 8×
“However, daily injections over 7 days led to a signi fi cant improvement in self-grooming behavior and anxiety [5].”
InfluentialSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Kim, E., Naisbitt, S., Hsueh, Y.-P., Rao, A., Rothschild, A., Craig, A. M., & Sheng, M. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.3.669 · Cited by 516
MEMBRANE-ASSOCIATED GUANYLATE KINASES REGULATE ADHESION AND PLASTICITY AT CELL JUNCTIONS
Funke, L., Dakoji, S., & Bredt, D. S. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133339 · Cited by 469 · cited 1×
“SAPAP3 proteins have an important role in the function of postsynaptic glutamatergic synapses in the area [5, 9].”
Postsynaptic organisation and regulation of excitatory synapses
Scannevin, R. H., & Huganir, R. L. (2000) · Nature Reviews Neuroscience · doi:10.1038/35039075 · Cited by 460 · cited 1×
“The SAPAP protein family can interact with postsynaptic molecules, including two multidomain scaffolding proteins — the SHANK protein family and PSD95, creating a regulator scaffolding complex at the excitatory synapse [7].”
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386 · cited 2×
“There is increasing evidence that glutamatergic mechanisms are implicated in OCD [38] and a role in excessive self-grooming by SAPAP3 KO mice is supported by short-term alleviation of this phenotype by ketamine [15] and by reports of ketamine ef fi cacy in patients with OCD [13].”
Takeuchi, M., Hata, Y., Hirao, K., Toyoda, A., Irie, M., & Takai, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11943 · Cited by 359
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347 · cited 3×
“There is increasing interest in the use of psilocybin and other tryptaminergic psychedelics to treat a range of psychedelic disorders including major depression, alcohol and nicotine addiction, and end of life anxiety [16].”
Cited by
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
Rogers, S. A., Heller, E. A., & Corder, G. F. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01964-9 · Cited by 30
“Clinical researchers have demonstrated that the therapeutic effects of serotonergic psychedelics in humans are mediated by increased cognitive flexibility following drug experience, a finding recapitulated in rodent models 31–34 .”
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 17
The Emergence of Psilocybin in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040555 · Cited by 16
“[35,47]”
Gattuso, J. J., Kong, G., Bezcioglu, B., Lu, D., Ekwudo, M. N., Wilson, C., Gubert, C., Hannan, A. J., & Renoir, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110648 · Cited by 11
Payamani, M., Abdollahi-Keyvani, S.-T., Sajjadi, M., Akhondzadeh, S., Javid, R., Nakhaei-Zadeh, R., Jalalian-Javadpour, M., & Vaseghi, S. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174027 · Cited by 8
Echefu, B. E., Becker, M., Stein, D. J., & Ornoy, A. (2025) · NeuroSci · doi:10.3390/neurosci6020027 · Cited by 8
“This presence of water could lead to extraneous behaviors quite unrelated to spatial learning, particularly in mice [95,97].”
Lazar, M., Brownstien, M., Botvinnik, A., Shevakh, C., Shahar, O., Lifschytz, T., & Lerer, B. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf022 · Cited by 6
Self-citationBruno, V., López-Canul, M., Richardson, B., Camarini, R., Marcourakis, T., & Gobbi, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368361 · Cited by 8
“Brownstien et al. (2024) and Gattuso et al. (2024) used a SAPAP3 knockout mouse model of compulsive-like behavior and also showed that psilocybin reduced grooming frequency.”
Richardson, B., Inserra, A., Pileggi, M., Prud’Homme, T., Bruno, V., Wan-Yan-Chan, D., Shareghi-Ghahreman, I., Nasini, S., Strand, T., Leyton, M., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111522 · Cited by 4
Gattuso, J. J., Bezcioglu, B., Wilson, C., Havaux, K., Hannan, A. J., & Renoir, T. (2025) · Psychedelics. · doi:10.61373/pp025i.0044 · Cited by 3
Drange, S., Cohen, J., Johansen, S. S., Dunkley, B. T., & Palner, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1819962 · Cited by 2
Psilocybin modulates social behaviour in male and female mice in a time-dependent manner
Shadani, S., McCoy, K., Ong, L., Greaves, E., Conn, K., Andrews, Z. B., & Foldi, C. J. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02450-x · Cited by 2
Bradshaw, A. J., Sharp, C., van der Merwe, B., Tremble, K., & Dentinger, B. T. M. (2026) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2025.2270 · Cited by 2
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03005-0 · Cited by 2
“In addition, the exclusion of lesioned SAPAP3 KO animals and WT controls might make it dif fi cult to elucidate — with precision — the exact drivers of Brownstien et al. (2024) ’ s fi ndings [3].”
Sharchaton, A., Parsha, S., Azerrad, S. P., Dekel, Y., Rabah, N., Páleníček, T., & Kurzbaum, E. (2026) · Journal of Fungi · doi:10.3390/jof12070486 · Cited by 1
“…suggests that natu-ral mushroom extracts may produce stronger or more prolonged effects than equivalent doses of synthetic psilocybin, possibly because accompanying indole alkaloids and other compounds, e.g., the betacarbolines, modulate or amplify the action of the primary compound [18,19].”
New treatments for OCD? Evidence for cannabinoids and psychedelics
Ameringen, M. V., Patel, V., Patterson, B. A., Hopkinson, P., & Rahat, M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.11.021 · Cited by 1
Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework
Ali, S. S., Carhart-Harris, R. L., & Sieg, K. G. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00626-4 · Cited by 1
Sex-dependent effects of psychedelics: review of evidence from rodent models
Marecki, R., Zaniewska, W., Hamed, A., Waszkiewicz, N., Baker, J. J., & Łukasiewicz, K. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1824073 · Cited by 1
“Self-grooming is another behavioral response studied in this context (57).”
Drange, S., Cohen, J., Johansen, S. S., Dunkley, B. T., & Palner, M. (2024) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/2bxe8 · Cited by 1
Validação do Appearance Anxiety Inventory
Dores, A. R., Freitas, M. J., Podlipskytė, A., Keep Fit Task force, & Corazza, O. (2025) · RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · doi:10.51126/zxyp5733
Brownstien, M., Lazar, M., Botvinnik, A., Pogodin, I., Lifschytz, T., & Lerer, B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03173-z
Self-citationLicinio, J., & Wong, M. (2025) · Psychedelics. · doi:10.61373/pp025d.0047
Rosal, S. P., & Faber, S. C. (2025) · Research Square · doi:10.21203/rs.3.rs-8000629/v1
Liu, X., Zhou, X., Meng, R., Chen, Y., Chen, Y., Highet, B., Curtis, M. A., Hirt, B., Yu, S., Zhou, J., et al. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70128
Ascone, F., Giangiacomo, D., & Trezza, V. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106761
Case Reports in Psychopharmacology, volume IV
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8059-2
Oña, G., Llagostera, C., Alvarez, O., Dueñas, R. M., González, D., & Soto-Angona, Ó. (2026) · Natural Product Research · doi:10.1080/14786419.2026.2683121
Jalalian-Javadpour, M., Yekta, B. G., Reyhani, N., Hajizamani, S., Azizi, A., Azad, N. K., Mohammadi, H., & Vaseghi, S. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101098
Rosal, S. P., & Faber, S. C. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100029
Bahrami, A., Yekta, B. G., & Baghdasarians, A. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.07.010
“Grooming behavior, defined as a sequence of movements directed toward cleaning and maintaining the fur, was also recorded as a compulsive-like behavioral measure (Brownstien et al., 2024; Hosseini et al., 2025; Zike et al., 2017).”
Retreat from racism: A psychedelic group experience for racial stress and trauma
Rosal, S. P., Faber, S., MacIntyre, M. M., & Williams, M. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100031
Spangemacher, M. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00013-7
Seillier, A., Dannan, G. I. E., & Seillier, L. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111924
Gattuso, J. J., Bezcioglu, B., Hendey, J., Payet, J. M., Phelan, Z. J., Hale, M. W., Hannan, A. J., & Renoir, T. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03879-8 · Cited by 1
Obsessive–Compulsive Disorder: Comorbidity, Biomarkers, Circuits, and Treatment Strategies
Zhang, X., Li, Z., Shen, L., Kong, B., Zhang, Q., Ke, Y., Tu, J., Wang, F., Yung, W., & Zhu, J. (2026) · MedComm · doi:10.1002/mco2.71067
Wang, J., Zheng, B., Yang, C., Wang, L., Zhang, W., Xu, J., & Zhuang, X. (2026) · International Journal of Pharmacology · doi:10.31083/ijp48587
Metadata
- Authors
- Brownstien, M., Lazar, M., Botvinnik, A., Shevakh, C., Blakolmer, K., Lerer, L., Lifschytz, T., & Lerer, B.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Corresponding author
- Lifschytz, Tzuri
- Lerer, Bernard
- Venue
- Molecular Psychiatry
- Published
- 2024-10-11
- Volume
- 30
- Issue
- 3
- Pages
- 1172-1183
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11835722
- OpenAlex
- W4403328142
- Cited by
- 30
- References
- 39
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 1
- FWCI
- 15.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- Parow Emtheobiosciences (ParowBio) Back of the yards algae sciences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psilocybin, obsessive-compulsive disorder, anxiety, long-term treatment outcomes, animal model of OCD, treatment-resistant OCD
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.